biotech26 days ago
North Immunology to go public via reverse merger with Aethlon Medical
North Immunology, a biotech incubated by hedge fund ADAR1 Capital, will merge with Nasdaq-listed Aethlon Medical to launch a long-acting bispecific antibody for atopic dermatitis. The combined entity, retaining the North Immunology name and trading under ticker NRTX, aims to begin Phase 1 trials in early 2027. The deal is backed by an $180 million private placement, with legacy Aethlon shareholders holding a 4.75% stake in the new company.